With many established products and services helping patients in 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and immune disease. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.Genzyme’s press releases and other company information are available at www.genzyme.com and by calling Genzyme’s investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States. About International Chemical Investors Group and Corden Pharma International Chemical Investors Group is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses. Since inception in 2004, ICIG has acquired 15 businesses, all of which have origins in major global chemical or pharmaceutical corporations and are independently managed. ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States. Corden Pharma group is the pharmaceutical market platform of ICIG, its companies offer contract development and contract manufacturing activities of advanced pharmaceutical intermediates, APIs and Drug Product formulations. Approximately 1,500 people support their customers with specialized technologies in all international markets. Important Information Genzyme has filed with the Securities and Exchange Commission a Solicitation/Recommendation Statement on Schedule 14D-9 relating to the tender offer by Sanofi-Aventis. Genzyme shareholders are advised to read the company's Solicitation/Recommendation Statement on Schedule 14D-9 because it contains important information. Shareholders may obtain a free copy of the Solicitation/Recommendation Statement on Schedule 14D-9, as well as any other documents filed by Genzyme in connection with the tender offer, free of charge at the SEC's website at http://www.sec.gov. In addition, investors can obtain free copies of these documents from Genzyme by directing a request to Genzyme at 500 Kendall Street, Cambridge, MA 02142, Attention: Shareholder Relations Department, or by calling 617-252-7500 and asking for the Shareholder Relations Department. This press release contains forward-looking statements regarding ICIG’s business plans, including the statements regarding the continued operation of Genzyme Pharmaceuticals as part of ICIG’s Corden Pharma group of companies; maintenance of a Corden Pharma Switzerland LLC manufacturing facility in Liestal, Switzerland and maintenance of commercial operations in the Boston, MA area; and the ability of Corden Pharma Switzerland LLC to supply products to Genzyme under the proposed supply agreement. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, the continued economic effectiveness of maintaining the current Genzyme pharmaceuticals business in its current locations, the ability of Corden Pharma to source critical raw materials and to operate manufacturing operations in a manner that successfully fulfills Genzyme’s requirements under the supply agreement, and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's Quarterly Report on Form 10-Q for the period ended September 30, 2010. Genzyme cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise these statements.
Genzyme ® is a registered trademark of Genzyme Corporation. All rights reserved.